Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-02
2011-10-25
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C514S042000, C514S043000
Reexamination Certificate
active
08044033
ABSTRACT:
The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient.
REFERENCES:
patent: 6537988 (2003-03-01), Lee
patent: 2005/0227929 (2005-10-01), Masferrer
Khamly et al. Expert Opin. Investig. Drugs (2005), vol. 14, pp. 607-628.
Ben-Josef et al. Journal of Clinical Oncology (2005), vol. 23, pp. 8739-8747.
Ayanian et al. Journal of Clinical Oncology (2003), vol. 21, pp. 1293-1300.
Koehne et al. Seminars in Oncology (2004), vol. 31, pp. 12-21.
Abushullaih et al., “Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience,”Cancer Invest., 20:3-10, 2002.
Blanquicett et al., “Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects,”Clin. Cancer Res., 11:8773-8781, 2005.
Chu, “Efficacy and safety of capacitabine therapy for colorectal cancer,”Amer. J. of Oncology Review, 2(5), Suppl. 3:1-28, 2003.
Cianchi et al., “Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer,”Gastroenterology, 121:1339-1347, 2001.
Demetri et al., “Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST,”Proc. Am. Soc. Clin. Oncol., 23:308, 2005.
Diaz Rubio et al., “Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study,”Proc. Am. Soc. Clin. Oncol., 23(16s):3535, 2005.
El-Rayes et al., “A Phase II Trial of Celecoxib, Irinotecan, and Capecitabine in Metastatic Colorectal Cancer,”Proc. Am. Soc. Clin. Oncol., 23(308):3677, 2005.
Escudier et al., “Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC),”Proc. Am. Soc. Clin. Oncol., 23(308):4510, 2005.
Fürstenberger et al., “Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer,”Br. J. Cancer, 94(4):524-531, 2006.
Grothey et al., “Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment,”J. Clin. Oncol., 22:1209-1214, 2004.
Hochster, “Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer,”Semin. Oncol., 33:S8-14, 2006.
International Search Report and Written Opinion issued in International Application No. PCT/US07/63236, mailed Sep. 25, 2007.
Jemal et al., “Cancer statistics, 2005,”CA Cancer J. Clin., 55:10-30, 2005.
Kerbel and Kamen, “The anti-angiogenic basis of metronomic chemotherapy,”Nat. Rev. Cancer, 6:423-436, 2004.
Lin et al.,“A phase II study of capecitabine and concomitant boost radiotherapy (XRT) in patients (pts) with locally advanced rectal cancer (LARC),”Proc. Am. Soc. Clin. Oncol., 23:269, 2005.
Lin et al., “Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?,”Am. J. Clin. Oncol., 29(3):232-239, 2006.
Masferrer et al., “Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors,”Cancer Res., 60:1306-1311, 2000.
Solomon et al., “Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention,”N. Engl. J. Med., 352:1071-1080, 2005.
Fulbright & Jaworski L.L.P.
Lewis Patrick
The Board of Regents of the University of Texas System
LandOfFree
Fluorocytidine derivatives and COX-2 inhibitors for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorocytidine derivatives and COX-2 inhibitors for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorocytidine derivatives and COX-2 inhibitors for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296346